Aligos Therapeutics Inc logo

Aligos Therapeutics Inc

NAS:ALGS (USA)   Ordinary Shares
$ 39.34 +0.49 (+1.26%) 11:09 PM EST
At Loss
P/B:
2.61
Market Cap:
$ 141.15M
Enterprise V:
$ 75.36M
Volume:
290.36K
Avg Vol (2M):
506.55K
Trade In:
Volume:
290.36K
At Loss
Avg Vol (2M):
506.55K

Business Description

Aligos Therapeutics Inc logo
Aligos Therapeutics Inc
NAICS : 541714 SIC : 2834
ISIN : US01626L1052

Share Class Description:

ALGS: Ordinary Shares
Description
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Name Current Vs Industry Vs History
Cash-To-Debt 8.2
Equity-to-Asset 0.57
Debt-to-Equity 0.18
Debt-to-EBITDA -0.1
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.27
Distress
Grey
Safe
Beneish M-Score -3.75
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 75.6
9-Day RSI 76.89
14-Day RSI 77.53
6-1 Month Momentum % 86.85
12-1 Month Momentum % 14.51

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.81
Quick Ratio 3.81
Cash Ratio 3.58

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -27.1
Shareholder Yield % 1.44

Financials (Next Earnings Date:2025-03-12 Est.)

ALGS's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ALGS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Aligos Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 5.997
EPS (TTM) ($) -17.105
Beta 2.93
Volatility % 187.63
14-Day RSI 77.53
14-Day ATR ($) 3.854498
20-Day SMA ($) 31.1175
12-1 Month Momentum % 14.51
52-Week Range ($) 6.76 - 42.9471
Shares Outstanding (Mil) 3.59

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aligos Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Aligos Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Aligos Therapeutics Inc Frequently Asked Questions

What is Aligos Therapeutics Inc(ALGS)'s stock price today?
The current price of ALGS is $39.34. The 52 week high of ALGS is $42.95 and 52 week low is $6.76.
When is next earnings date of Aligos Therapeutics Inc(ALGS)?
The next earnings date of Aligos Therapeutics Inc(ALGS) is 2025-03-12 Est..
Does Aligos Therapeutics Inc(ALGS) pay dividends? If so, how much?
Aligos Therapeutics Inc(ALGS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1